Articles

Duopharma Biotech Signs with the Government of Malaysia to Supply Russia’s COVID-19 Vaccine to Malaysia

● Following the signing with the Government of Malaysia, Duopharma Biotech’s Group MD
confirmed the Company’s readiness and alignment with Malaysia’s COVID-19 national
immunisation programme

Duopharma Biotech Maintains Forward Momentum with Robust Fundamentals

➢ Duopharma Biotech Berhad’s 20th AGM reinforces the Group’s role as a pharmaceutical and
healthcare leader committed to actively supporting the health and betterment of Malaysia
through the coronavirus crisis and beyond
➢ Robust business fundamentals and core values of the Group continue to maintain our
forward momentum and to enable ventures into specialist and niche biotherapies, said
Duopharma Biotech leadership

Duopharma Biotech Announces 1 for 3 Bonus Issue After Sterling 1st Quarter 2021

➢ The 1-for-3 proposed bonus issue would entail the issuance of up to 239,926,896 new
ordinary shares
➢ 1Q 2021 PBT leaps to RM23.18 million, soaring more than 30% from the RM17.73 million
posted in the preceding year corresponding period
➢ Record profits posted on back of increased quarterly revenue of RM166.45 million (2020:
RM158.71 million)

Duopharma Biotech Sets out to Expand Health and Beauty Range: Launch of Flavettes Effervescent Glamz

“We are continuing to expand our consumer healthcare range through the inclusion of a beauty proposition to address the growing demand,” says Duopharma Biotech GMD
Themed ‘Be Seri-Seri Inside Out’, the launch campaign introduces new ‘best friend’ brand ambassadors and a nationwide Instagram contest with attractive prizes

Duopharma Biotech CHAMPS® and Nasom CHAMPIONS Autism Awareness Fundraiser Featuring Art Crafted by Autism Children

Kuala Lumpur, 9 April 2021 – This year, in conjunction with World Autism Month, Malaysia’s
largest vitamin brand for children, CHAMPS® – Mother’s Choice for Champions, together with
the charitable non-governmental organisation The National Autism Society of Malaysia
(NASOM), marks their fifth year in collaboration to augment nationwide awareness towards
the acceptance of Autism in Malaysia.

Duopharma Biotech Fortifies Ethical Culture with ISO37001 Achievement and First Malaysia Pharma Company to Win BEIM FIVE Petals Gold Ethics Award

The ISO37001 Anti-Bribery Management System achievement together with the BEIM award is another testament to Duopharma Biotech’s proactive commitment to promulgating a culture of ethics and integrity, says Group MD
Duopharma Biotech is the first Pharmaceutical Company in Malaysia to be awarded the Five Petal Business Ethics Institute of Malaysia (BEIM) Gold Ethics Award’

Duopharma Biotech Maintains Profit Momentum

➢ 4Q PBT leaps to RM20.47 million, a 47% increase over previous corresponding period
➢ EPS climbs to 8.46 sen for the year from previous corresponding year’s 8.25 sen
➢ The Government of Malaysia’s extension of existing Supply Agreements with government
hospitals, clinics stabilises a significant portion of group revenue, placing Duopharma Biotech
in a better position to mobilise resources to intensify foray into specialty and niche products
➢ Supply of Covid-19 vaccine also expected to contribute positively to future earnings

Duopharma Biotech to Supply 6.4 Million Doses of The Russian COVID-19 Vaccine to The Nation 

KUALA LUMPUR, 26 JANUARY 2021 – Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) through its wholly-owned subsidiary Duopharma (M) Sendirian Berhad (“DMSB”) has confirmed it will procure and supply to Malaysia’s Ministry of Health (“MoH”) the COVID-19 vaccine known as “Sputnik V” developed by the Gamaleya National Research Institute of Epidemiology and Microbiology (“Gamaleya”). 

Duopharma Biotech Signs MOU with KPJ Healthcare Berhad to Collaborate Initiatives of Halal Pharmaceuticals

Kuala Lumpur, December 18, 2019 – Duopharma Biotech Berhad (formerly known as CCM Duopharma Biotech Berhad) (“Duopharma Biotech”) today unveiled its new corporate logo and name at an external rebranding launch. The Company obtained shareholders’ approval for the new corporate identity earlier this year. Duopharma Biotech, which is majority owned by Permodalan Nasional Berhad (PNB), is the largest Malaysian pharmaceutical manufacturer and trading company.

Duopharma Biotech Posts Another Strong Quarter Registering PBT of RM18.57 Million

KUALA LUMPUR, 12 NOVEMBER 2020 – Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) has posted a solid set of financial results for the third quarter ended 30 September 2020 with profit before tax holding steady at RM18.57 million (2019: RM19.77 million) against revenue of RM133.77 million (2019: RM142.86 million) despite impact of Covid-19 pandemic.